AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) shares were up 3.5% during trading on Wednesday . The company traded as high as $27.24 and last traded at $26.85, with a volume of 479,196 shares. The stock had previously closed at $25.95.

A number of research analysts have commented on AMAG shares. Jefferies Group raised AMAG Pharmaceuticals from an “underperform” rating to a “hold” rating and increased their target price for the stock from $16.00 to $19.00 in a report on Monday, March 28th. Ladenburg Thalmann downgraded AMAG Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, March 28th. Leerink Swann cut their price target on AMAG Pharmaceuticals from $25.00 to $23.00 and set an “outperform” rating on the stock in a report on Monday, March 28th. Robert W. Baird cut their price target on AMAG Pharmaceuticals from $26.00 to $25.00 and set an “outperform” rating on the stock in a report on Monday, March 28th. Finally, Zacks Investment Research downgraded AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, April 29th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $38.20.

The firm has a market cap of $924.96 million and a PE ratio of 89.46. The company’s 50 day moving average is $23.64 and its 200-day moving average is $23.49.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings data on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.94 EPS for the quarter, missing the Zacks’ consensus estimate of $1.11 by $0.17. The company had revenue of $117.60 million for the quarter, compared to analyst estimates of $124.83 million. The firm’s quarterly revenue was up 41.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.17 EPS. On average, equities analysts anticipate that AMAG Pharmaceuticals Inc. will post $5.20 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in AMAG. Rhumbline Advisers boosted its stake in AMAG Pharmaceuticals by 10.1% in the fourth quarter. Rhumbline Advisers now owns 37,447 shares of the specialty pharmaceutical company’s stock worth $1,131,000 after buying an additional 3,420 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in AMAG Pharmaceuticals by 570.4% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 49,608 shares of the specialty pharmaceutical company’s stock worth $1,498,000 after buying an additional 42,208 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in AMAG Pharmaceuticals by 6.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 62,716 shares of the specialty pharmaceutical company’s stock worth $1,893,000 after buying an additional 3,903 shares in the last quarter. Bank of Montreal Can boosted its stake in AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock worth $2,287,000 after buying an additional 73,152 shares in the last quarter. Finally, LSV Asset Management boosted its stake in AMAG Pharmaceuticals by 19.9% in the fourth quarter. LSV Asset Management now owns 93,842 shares of the specialty pharmaceutical company’s stock worth $2,833,000 after buying an additional 15,600 shares in the last quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.